VivoSeq
Other

Priapism

2

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Priapism is an early-stage landscape with 2 programs across 2 companies. The most active players are Viatris Specialty LLC, Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

67/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Viatris Specialty LLC

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 22

Sildenafil

Viatris Specialty LLC

Tadalafil

Eli Lilly

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

3

clinical trials

Completed2 · 67%
Withdrawn1 · 33%

Clinical Trials

Trial Activity

Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia
Completed·JJohns Hopkins University·Phase 2·NCT00940901·13 enrolled
Investigation of the Protective Effect of Alpha Lipoic Acid on Ischemic Reperfusion Damage in Ischemic Priapism in Rats
Completed·TTrabzon Kanuni Education and Research Hospital·N/A·NCT07391709·18 enrolled
Tadalafil for Treatment of Priapism in Men With Sickle Cell Anemia
Withdrawn·JJohns Hopkins University·Phase 2·NCT00538564

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)